Background and Aims: Bronchiolitis obliterans syndrome (BOS) is a rare, progressive and irreversible airway disease associated with significant mortality after allogeneic hematopoietic stem-cell transplantation (HSCT). Combination treatment with budesonide/formoterol 160/4.5 μg, montelukast and n-acetylcysteine showed benefit with BOS patients in our previous study. In this study, we investigated the therapeutic effect of high-dose budesonide/formoterol 320/9 μg among patients who were diagnosed with BOS after allogeneic HSCT and who were already having treatment with budesonide/formoterol 160/4.5 μg.
The Catholic University of Korea, School of Medicine, South Korea Background and Aims: Bronchiolitis obliterans syndrome (BOS) is a rare, progressive and irreversible airway disease associated with significant mortality after allogeneic hematopoietic stem-cell transplantation (HSCT). Combination treatment with budesonide/formoterol 160/4.5 μg, montelukast and n-acetylcysteine showed benefit with BOS patients in our previous study. In this study, we investigated the therapeutic effect of high-dose budesonide/formoterol 320/9 μg among patients who were diagnosed with BOS after allogeneic HSCT and who were already having treatment with budesonide/formoterol 160/4.5 μg.
Methods: Sixty-nine patients diagnosed BOS after an allogeneic HSCT who already had been treated with budesonide/formoterol 160/4.5 μg and increased the drug dose to 320/9 μg were enrolled in this study. Pulmonary function test (PFT) and COPD assessment test (CAT) were performed before and after changing of the drug dose. Efficacy was assessed within 3 months after increasing the drug dose; the primary variable was changes in forced expiratory volume in 1 second (FEV1) and CAT score. Safety was assessed as the incidence of pneumonia within 3 months after increasing the drug dose.
Results: After 3 months of high-dose budesonide/formoterol treatment (budesonide/formoterol 320/9 μg), mean FEV1 increased 29 mL (budesonide/formoterol 160/4.5 μg, 1.68 L vs budesonide/formoterol 320/9 μg, 1.71 L), P = 0.468. Mean CAT score also decreased from 17.8 to 17.5, (P = 0.711). In safety assessment, 7 patients got pneumonia within 3 months before budesonide/formoterol 320/9 μg treatment and 7 patients got pneumonia within 3 months after budesonide/formoterol 320/9 μg treatment and there was no significant difference between two groups.
Conclusion: There were no significant differences between budesonide/formoterol 320/9 μg and budesonide/formoterol 160/4.5 μg treatment to pulmonary function and quality of life with diagnosed BOS patients after allogeneic HSCT. And there was no significant difference in the incidence of pneumonia, indicating that there was no safety difference between two doses. The University of Tokyo, Japan Background and Aims: Chronic obstructive pulmonary disease (COPD) is a common disease worldwide and is burdensome particularly in the elderly. The aim of this study was to evaluated the effect of daikenchu-to, a most prescribed traditional Japanese herbal Kampo medicine, on COPD exacerbations in elderly patients who were discharged after hospitalization for a COPD exacerbation. The primary outcome was COPD exacerbations requiring hospitalization or death. The secondary outcome was the frequency of COPD exacerbations, including exacerbations in the outpatient settings, per 30 days.
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Methods: We used Japanese Diagnosis Procedure Combination
Database (DPC) with outpatient's data. Using the covariates including age, sex, body mass index, Barthel index, comorbid diagnosis as well as treatments before and during initial hospitalization, propensity scores were calculated. Then 1-to-4 matching with propensity scores was conducted between patients whom dai-kenchu-to has been prescribed and whom dai-kenchu-to has not been prescribed. Log rank test was performed to compare the survival curves for hospitalization for COPD exacerbations or death. Poisson regression with generalized estimation equation was performed to compare the overall frequency of COPD exacerbations. A two tailed significance level of 0.05 was used in all statistical analysis.
Results: Before propensity score matching, number of patients in dai-kenchu-to group and in non-dai-kenchu-to group were 740 and 19,595, respectively. After 1-to-4 propensity score matching, number of patients in each group were 355 and 1,420. The log rank test comparing survival curves from the two groups did not show a statistically significant difference in propensity score matched patients. Incidence rate ratio of the frequency of COPD exacerbations per 30 days was 0.71 (95% confidence interval 0.54 -0.94; P = 0.018) after propensity score matching.
Conclusion:
Dai-kenchu-to may reduce overall frequency of COPD exacerbations but not severe exacerbations requiring hospitalization. 
